|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CASE 1 | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | |
| Tumor Description | | | | | **Grade** | | | | | | **Tumor Size** | | | | | | | |
| Primary Site | | C76.0 | | | **Clinical** | | | | 9 | | **Clinical** | | | | 000 | | | |
| Laterality | | 0 | | | **Pathological** | | | | 9 | | **Pathological** | | | | 999 | | | |
| Histology | | 8070 | | | **Post Therapy (yc)** | | | | Blank | | **Summary** | | | | 000 | | | |
| Behavior | | 3 | | | **Post Therapy (yp)** | | | | Blank | |  | | | | | | | |
| AJCC Staging Items | | | | | | | | | | | | | | | | | | | |
| Clinical T | cT0 | | **Pathological T** | | | | blank | **Post-therapy cT** | | | |  | | **Post-therapy pT** | | |  | | |
| cT Suffix | Blank | | **pT Suffix** | | | | blank | **ypT Suffix** | | | |  | | **ypT Suffix** | | |  | | |
| Clinical N | cN2b | | **Pathological N** | | | | blank | **Post-therapy cN** | | | |  | | **Post-therapy pN** | | |  | | |
| cN Suffix | (f) | | **pN Suffix** | | | | blank | **ypN Suffix** | | | |  | | **ypN Suffix** | | |  | | |
| Clinical M | cM0 | | **Pathological M** | | | | blank | **Post-therapy M** | | | |  | | **Post-therapy M** | | |  | | |
| Stage Group | 4A | | **Stage Group** | | | | 99 | **Stage Group** | | | |  | | **Stage Group** | | |  | | |
| SS2018/EOD | | | | | | | | | | | | | | | | | |
| Summary Stage 2018 | | | | 3 | |  | | | | | | | | | | | |
| Extent of Disease | | | | | | | | | | | | | | | | | |
| EOD Primary Tumor | | | | 800 | | **EOD Regional Nodes** | | | | 250 | | | **EOD Mets** | | | 00 | |

|  |  |
| --- | --- |
| Regional Nodes Positive | 95 |
| Regional Nodes Examined | 95 |
| SSDI | | **LN H/N VI-VII** | | **0** | **LN H/N Other** | | 0 |
| Schema Discriminator 1 | 3 | **ENE Pathological** | | X.9 | LN H/N levels I-III | | 2 |
| ENE Clinical | 0 | **LN Size of Mets** | | 28.0 | LN H/N levels IV-V | | 0 |
| Treatment | | | | | | | |
| Surgery Codes | | | | **Systemic Therapy Codes** | | | |
| Diagnostic Staging Procedure | | | 00 | **Chemotherapy** | | 02 | |
| Surgical Procedure of Primary Site | | | 00 | **Hormone Therapy** | | 00 | |
| Scope of RLN Node Surgery | | | 1 | **Immunotherapy** | | 00 | |
| Radiation | | | | | | | |
| Phase | | | 1 2 3 |  | | 1 2 3 | |
| Primary Treatment Volume | | | 29 29 29 | **Dose Per fraction** | | 00200 00180 00160 | |
| Draining LN | | | 01 01 01 | **Fractions** | | 035 035 035 | |
| Modality | | | 02 02 02 | Total Dose | | 007000 006300 005600 | |
| EB Planning Technique | | | 05 05 05 |  | |  | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CASE 2 | | | | | | | | | | | | | | | | | | |
| Tumor Description | | | | | **Grade** | | | | | | **Tumor Size** | | | | | | | |
| Primary Site | | C10.9 | | | **Clinical** | | | | 9 | | **Clinical** | | | | 023 | | | |
| Laterality | | 0 | | | **Pathological** | | | | 9 | | **Pathological** | | | | 999 | | | |
| Histology | | 8085 | | | **Post Therapy (yc)** | | | |  | | **Summary** | | | | 023 | | | |
| Behavior | | /3 | | | **Post Therapy (yp)** | | | |  | |  | | | | | | | |
| AJCC Staging Items | | | | | | | | | | | | | | | | | | | |
| Clinical T | cT2 | | **Pathological T** | | | |  | **Post-therapy cT** | | | |  | | **Post-therapy pT** | | | |  | |
| cT Suffix |  | | **pT Suffix** | | | |  | **ypT Suffix** | | | |  | | **ypT Suffix** | | | |  | |
| Clinical N | cN1 | | **Pathological N** | | | |  | **Post-therapy cN** | | | |  | | **Post-therapy pN** | | | |  | |
| cN Suffix | (f) | | **pN Suffix** | | | |  | **ypN Suffix** | | | |  | | **ypN Suffix** | | | |  | |
| Clinical M | cM0 | | **Pathological M** | | | |  | **Post-therapy M** | | | |  | | **Post-therapy M** | | | |  | |
| Stage Group | 1 | | **Stage Group** | | | | 99 | **Stage Group** | | | |  | | **Stage Group** | | | |  | |
| SS2018/EOD | | | | | | | | | | | | | | | | |
| Summary Stage 2018 | | | | 3 | |  | | | | | | | | | | |
| Extent of Disease | | | | | | | | | | | | | | | | |
| EOD Primary Tumor | | | | 100 | | **EOD Regional Nodes** | | | | 300 | | | **EOD Mets** | | | 00 |

|  |  |  |
| --- | --- | --- |
| Regional Nodes Positive | | 95 |
| Regional Nodes Examined | | 95 |
| SSDIs | | | | | | |
| Schema Discriminator 2 | | 2 | **ENE Pathological** | | X.9 | |
| ENE Clinical | | 1 | **LN Size of Mets** | | 40.0 | |
| Treatment | | | | | | | |
| Surgery Codes | | | | **Systemic Therapy Codes** | | | |
| Diagnostic Staging Procedure | 00 | | | **Chemotherapy** | | 02 | |
| Surgical Procedure of Primary Site | 00 | | | **Hormone Therapy** | | 00 | |
| Scope of Regional Lymph Node Surgery | 1 | | | **Immunotherapy** | | 00 | |
| Radiation | | | | | | | |
| Primary Treatment Volume | 22 22 | | | **Dose per FX** | | 00200 00200 | |
| Draining LN | 01 01 | | | **Fractions** | | 020 015 | |
| Modality | 03 03 | | | **Total Dose** | | 004000 003000 | |
| EB Planning technique | 05 05 | | |  | |  | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CASE 3 | | | | | | | | | | | | | | | | | | |
| Tumor Description | | | | | **Grade** | | | | | | **Tumor Size** | | | | | | | |
| Primary Site | | C09.9 | | | **Clinical** | | | | 9 | | **Clinical** | | | | 999 | | | |
| Laterality | | 1 | | | **Pathological** | | | | C | | **Pathological** | | | | 010 | | | |
| Histology | | 8085 | | | **Post Therapy (yc)** | | | |  | | **Summary** | | | | 010 | | | |
| Behavior | | /3 | | | **Post Therapy (yp)** | | | |  | |  | | | | | | | |
| AJCC Staging Items | | | | | | | | | | | | | | | | | | | |
| Clinical T | cT1 | | **Pathological T** | | | | pT1 | **Post-therapy cT** | | | |  | | **Post-therapy pT** | | | |  | |
| cT Suffix |  | | **pT Suffix** | | | |  | **ypT Suffix** | | | |  | | **ypT Suffix** | | | |  | |
| Clinical N | cN1 | | **Pathological N** | | | | pN2 | **Post-therapy cN** | | | |  | | **Post-therapy pN** | | | |  | |
| cN Suffix | (f) | | **pN Suffix** | | | |  | **ypN Suffix** | | | |  | | **ypN Suffix** | | | |  | |
| Clinical M | cM0 | | **Pathological M** | | | | cM0 | **Post-therapy M** | | | |  | | **Post-therapy M** | | | |  | |
| Stage Group | I | | **Stage Group** | | | | 2 | **Stage Group** | | | |  | | **Stage Group** | | | |  | |
| SS2018/EOD | | | | | | | | | | | | | | | | |
| Summary Stage 2018 | | | | 3 | |  | | | | | | | | | | |
| Extent of Disease | | | | | | | | | | | | | | | | |
| EOD Primary Tumor | | | | 100 | | **EOD Regional Nodes** | | | | 500 | | | **EOD Mets** | | | 00 |

|  |  |  |
| --- | --- | --- |
| Regional Nodes Positive | 07 | |
| Regional Nodes Examined | 26 | |
| SSDIs | | | | | | |
| Schema Discriminator 2 | 2 | | **ENE Pathological** | | X.1 | |
| ENE Clinical | 0 | | **LN Size of Mets** | | 30.0 | |
| Treatment | | | | | | | |
| Surgery Codes | | | | **Systemic Therapy Codes** | | | |
| Diagnostic Staging Procedure | | 00 | | **Chemotherapy** | | 02 | |
| Surgical Procedure of Primary Site | | 31 | | **Hormone Therapy** | | 00 | |
| Scope of Regional Lymph Node Surgery | | 5 | | **Immunotherapy** | | 00 | |
| Radiation | | | | | | | |
| Primary Treatment Volume | | 22 22 | | **Dose per FX** | | 00200 00180 | |
| Draining LN | | 01 01 | | **Fractions** | | 030 030 | |
| Modality | | 02 02 | | **Total Dose** | | 006000 005400 | |
| EB Planning technique | | 05 05 | |  | |  | |